Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.27 and traded as low as $0.25. Northwest Biotherapeutics shares last traded at $0.35, with a volume of 12,179,951 shares trading hands.
Northwest Biotherapeutics Price Performance
The stock has a market cap of $490.69 million, a P/E ratio of -4.40 and a beta of -0.67. The stock has a 50-day simple moving average of $0.24 and a 200-day simple moving average of $0.27.
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last announced its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The company had revenue of $0.23 million for the quarter.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
See Also
- Five stocks we like better than Northwest Biotherapeutics
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally
- What is the Euro STOXX 50 Index?
- Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar
- What is the Dogs of the Dow Strategy? Overview and Examples
- Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
